Navigation Links
Meso Scale Discovery Launches V-PLEX™ Multiplex Biomarker Immunoassays
Date:9/11/2013

Rockville, MD (PRWEB) September 11, 2013

There is a significant unmet need for accurate and precise biomarker tests for clinical trials, drug development and medical research. V-PLEX simultaneously measures multiple biomarkers using assays that are grouped into panels for optimal and consistent performance. The V-PLEX immunoassay menu focuses on emerging biomarkers that are generally not available on traditional diagnostics platforms, giving researchers access to new types of tests.

“We’re very excited that the life science and clinical research community will now have access to new biomarker tests through V-PLEX,” said Jacob Wohlstadter, President and CEO. “The lack of validated tests for biomarkers has challenged pharmaceutical companies and been a major limitation for important medical research. Together with our recently launched QuickPlexSQ 120 instrument, V-PLEX offers unprecedented access to high-quality immunoassays in a flexible and affordable format.”

Validated tests enable long-term programs like clinical trials and epidemiological studies by providing sustainable, reliable measurements of clinically significant markers. These tests have defined, rigorous specifications for analytical performance, and each new lot passes strict requirements before release. Results from validated tests are viewed with greater confidence and are often required for regulatory approvals.

“The practical implications of V-PLEX are significant, particularly for laboratories and CROs that run biomarker tests as their primary business” said Dr. James Wilbur, General Manager. “In the absence of available tests, these laboratories must bear the burden of developing their own tests and conducting formal validations, which is simply unaffordable for many markers. With V-PLEX, these laboratories can now offer a wide menu of biomarkers in a fully-validated format, and, through the use of V-PLEX panels, reduce their labor, costs and sample consumption even further.”

V-PLEX immunoassays, using MSD’s proprietary electrochemiluminescence (ECL) MULTI-ARRAY® technology, are developed under rigorous design control and are fully validated according to “Fit for Purpose” principles. They are compatible with either MSD’s SECTOR® or QuickPlex instrument lines. The initial menu of V-PLEX immunoassays includes the most important cytokines, chemokines, and Alzheimer’s disease biomarkers.

For more information on V-PLEX immunoassays, call Customer Service at 1-240-314-2795; email customerservice@mesoscale.com; or visit http://www.mesoscale.com/V-PLEX.

Read the full story at http://www.prweb.com/releases/immunoassay/news/prweb11109813.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. CPUsage Launches Massive Scale Cloud Computing Platform at TechCrunch Disrupt
2. Breakthrough in sensing at the nanoscale
3. LIMS 24/7 and Ayrris: Big-Data Lab Management for Production-Scale NGS
4. Broad-scale genome tinkering with help of an RNA guide
5. Meso Scale Discovery Launches New Quickplex™ SQ 120 Multiplex Immunoassay Instrument
6. Unisense FertiliTech to Present Large Scale Time-lapse Data Analysis to Improve IVF Treatment
7. Cross-Cultural Qualitative Research for Simultaneous Scale Development, New Life Science Webinar Hosted by Xtalks
8. United Airlines and AltAir Fuels to Bring Commercial-Scale, Cost-Competitive Biofuels to Aviation Industry
9. Study led by GW professor provides better understanding of waters freezing behavior at nanoscale
10. Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
11. CIC nanoGUNE launches Simune, an atomic-scale simulations service for companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
(Date:6/23/2016)... PUNE, India , June 23, 2016 /PRNewswire/ ... culture media market research report to its pharmaceuticals ... company profiles, product details and much more. ... market spread across 151 pages, profiling 15 companies ... now available at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . ...
Breaking Biology Technology:
(Date:6/20/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring announced that ... has secured the final acceptance by all three ... Access Systems (MAS) installed. Furthermore, Securus will have ... installed by October, 2016. MAS distinguishes between legitimate ...
(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
(Date:6/9/2016)... Finland , June 9, 2016 ... National Police deploy Teleste,s video security solution to ensure the ... France during the major tournament ... data communications systems and services, announced today that its video ... Prefecture to back up public safety across the ...
Breaking Biology News(10 mins):